玻璃体腔内注射康柏西普治疗继发性黄斑水肿疗效观察

发布时间：2018-03-20 01:15

本文选题：康柏西普　切入点：玻璃体腔注射　出处：《中国医学创新》2016年31期 　论文类型：期刊论文

【摘要】：目的:观察康柏西普玻璃体腔注射治疗继发性黄斑水肿有效性和安全性。方法:对继发于糖尿病视网膜病变及视网膜静脉阻塞的黄斑水肿患者35眼,予以玻璃体腔内注射康柏西普(0.5 mg,0.05 m L)进行治疗,随访1~3个月,观察治疗前及治疗后1 d,1周,1、2、3个月患者最佳矫正视力,黄斑区中心厚度及眼压的变化。结果:患者最佳矫正视力在玻璃体腔注药后1周,1、2、3个月均较治疗前明显提高,比较差异均有统计学意义(P0.001);黄斑区中心厚度在治疗后1周,1、2、3个月较治疗前明显降低,比较差异均有统计学意义(P0.001);眼压在注药后1 d,1周,1、2、3个月均无明显升高,比较差异均无统计学意义(P0.005)。结论:玻璃体腔内注射康博西普是目前治疗继发性黄斑水肿的有效而且安全的治疗手段,但部分患者黄斑水肿复发,需再次给药。
[Abstract]:Objective: to observe the efficacy and safety of Corbeseptide intravitreal injection in the treatment of secondary macular edema. Methods: 35 eyes with macular edema secondary to diabetic retinopathy and retinal vein occlusion were treated. The patients were followed up for 1 ~ 3 months. The best corrected visual acuity was observed 1 week before treatment and 1 day after treatment, and the best corrected visual acuity was 3 months. Results: the best corrected visual acuity (BCVA) was significantly improved at 1 week and 3 months after intravitreal injection. The central thickness of macular area decreased significantly at 1 week and 3 months after treatment, and the difference was statistically significant (P 0.001), and IOP did not increase at 1 week or 1 week after injection, but there was no significant increase in intraocular pressure at 3 months after treatment, and there was no significant difference in the thickness of macular area between 1 week and 3 months after treatment, and there was no significant increase in intraocular pressure at 1 week or 1 week after injection, and there was no significant increase at 3 months after treatment. Conclusion: intravitreal injection of Combosemide is an effective and safe method for the treatment of secondary macular edema, but some patients have relapsed macular edema and need to be given drugs again.
【作者单位】：南京市江宁医院;
【分类号】：R774.5

【相似文献】